Nitto Denko Corporation (XETRA: ND5.DE): New Anti-fibrosis Drug With Molecular Targeting DDS Completed Phase-1a Dose Escalation
4/22/2014 8:07:17 AM
OSAKA, Japan--(BUSINESS WIRE)--Nitto Denko Corporation (Nitto) (TOKYO:6988) (ISIN:JP3684000007) has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof.Yoshiro Niitsu of Sapporo Medical University. In June 2013, Nitto initiated a phase-1 clinical study in the US, and it is happy to announce that dosing in healthy volunteers has been completed. Currently, Nitto is advancing the drug to phase-1/2 clinical study in patients for the assessment of safety and efficacy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by